

SCOPE: ALS, CCT	
MEDICATION:	RACEMIC EPINEPHRINE
INTERVENTION:	<p><u>Classification:</u> Sympathomimetic, Bronchodilator</p> <p><u>Actions:</u> Stimulates alpha and beta receptors within the sympathetic nervous system to relax smooth muscle of the bronchi</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Concurrent use or within 2 weeks of MAO inhibitors <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Hypertension • Cardiac disease • Diabetes • Seizures • Thyroid disease • Lactation • PREGNANCY RISK FACTOR: C <p><u>Dosage:</u></p> <ol style="list-style-type: none"> I. <u>Croup/Upper Airway Obstruction:</u> <ol style="list-style-type: none"> a. Adult/Pediatric: <ol style="list-style-type: none"> i. SVN: 2.25% unit dose diluted to 3ml NS total volume II. <u>Bronchiolitis:</u> <ol style="list-style-type: none"> a. Adult/Pediatric: <ol style="list-style-type: none"> i. SVN: 2.25% unit dose diluted to 3ml NS total volume <ol style="list-style-type: none"> 1. May repeat x2 every 20 minutes <p><u>Onset of Action:</u> ~1 minute</p> <p><u>Duration:</u> 1-3 hours</p> <p><u>Adverse Effects:</u> Tachycardia, Increased Blood Pressure, Tremors, Anxiety, Insomnia</p> <p><u>Special Considerations:</u></p> <ol style="list-style-type: none"> I. Can have a dangerous interaction with MAO inhibitors

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 1